Compare Deccan Healthcar with Similar Stocks
Stock DNA
Healthcare Services
INR 36 Cr (Micro Cap)
27.00
32
0.00%
0.00
1.30%
0.35
Total Returns (Price + Dividend) 
Deccan Healthcar for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Deccan Health Care Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
Deccan Health Care Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 5 February 2026, driven primarily by a shift in technical indicators. Despite this improvement, the healthcare services company continues to face challenges in its fundamental and financial metrics, reflecting a complex investment outlook.
Read full news article
Deccan Health Care Ltd Hits All-Time Low Amid Continued Market Underperformance
Deccan Health Care Ltd’s stock price has plunged to a new all-time low of Rs.13, marking a significant milestone in its ongoing decline. The healthcare services company has experienced sustained underperformance relative to the broader market and its sector peers, reflecting persistent pressures on its financial metrics and market valuation.
Read full news article
Deccan Health Care Ltd is Rated Strong Sell
Deccan Health Care Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 January 2026, providing investors with the latest insights into its performance and outlook.
Read full news article Announcements 
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
21-Jan-2026 | Source : BSECertificate under Reg 74(5) for Quarter ended Dec 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
10-Jan-2026 | Source : BSEResignation of CS and compliance officer.
Closure of Trading Window
27-Dec-2025 | Source : BSEDear Sir/Madam Pursuant to the Code of Conduct for Regulating Monitoring & Reporting Trading by Insiders of the Company under SEBI (Prohibition of Insider Trading) Regulations 2015 we would like to inform you that the trading window for the purpose of trading in shared of the Company by its Designated Persons and its Immediate relatives shall remain closed from 01st January 2026 till 48 hours after the announcement of the unaudited financial results for the quarter ended 31st December 2025. The date of the board meeting for the consideration and declaration of unaudited financial results for the quarter ended 31st December 2025 will be intimated in due course. It is the responsibility of each insider and insiders immediate relatives to ensure compliance with the insider code of the company and shall not deal in the companys securities during the above period of trading window closure Thank you Yours Sincerely
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Minto Purshotam Gupta (13.68%)
None
46.36%
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is -3.34% vs 6.70% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 279.17% vs 100.00% in Jun 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 28.51% vs 19.21% in Sep 2024
Growth in half year ended Sep 2025 is 29.21% vs 5.95% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is 24.11% vs 50.02% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -24.82% vs 3,325.00% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 25.67% vs 32.67% in Mar 2024
YoY Growth in year ended Mar 2025 is -22.15% vs 313.89% in Mar 2024






